Drug intelligence / Profile preview

Amicidin-alpha PFC

Development stage
Preclinical
Lead developer
Macro Biologics
Modality
Peptides, Recombinant Proteins and Enzymes
Administration
Topical
01

Overview

Amicidin-alpha PFC is a first-in-class biological therapeutic developed by Macro Biologics (formerly Amicrobe) for the prevention and treatment of wound contamination and infection in military prolonged field care (PFC) settings. It is a dry powder formulation of Amicidin-alpha, a synthetic antimicrobial protein that mimics the dual protective activities of skin. Upon application to open traumatic wounds, the powder absorbs fluid to form a protective gel barrier that provides a physical and electrostatic block against contaminants while exerting broad-spectrum microbicidal activity against Gram-positive and Gram-negative bacteria (including multi-drug resistant organisms) and Candida species for up to 72 hours.

Brand names
Amicidin-alpha PFCAmicidin-α PFC
Other names
Amicidin-alpha PFCAmicidin-α PFC

Beyond the preview

Go deeper on Amicidin-alpha PFC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amicidin-alpha PFC.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call